-
-
-
-
-
-
-
FDA Approves Takeda’s EOHILIA (budesonide oral suspension), the First and Only Oral Treatment in the U.S. for Eosinophilic Esophagitis (EoE)
-
-
-
-
-
-
-
Takeda Named Global Top Employer for Seventh Consecutive Year
-
-
-
-
-
-
-
Takeda (TAK) Announces Late-Breaking Data from Phase 2b Study of TAK-279
-
-
-
-
-
-
-
Takeda (TAK) Provides Update on EXKIVITY
-
-
-
-
-
-
-
Takeda Announces Positive Topline Results from Phase 2b Study Evaluating TAK-279, a Highly Selective Oral TYK2 Inhibitor, for the Treatment of Active Psoriatic Arthritis
-
-
-
-
-
-
-
Takeda and HUTCHMED Announce New Drug Application (NDA) for Fruquintinib for Treatment of Previously Treated Metastatic Colorectal Cancer Granted Priority Review
-
-
-
-
-
-
-
Takeda Announces New U.S. Corporate Social Responsibility (CSR) Program Partners
-
916,770 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All